The nine-valent HPV vaccine is suitable for women aged 16 to 26 who have no allergic reaction to the vaccine. The nine-valent HPV vaccine is currently approved for marketing in China. The vaccination is for women aged 16 to 26 years old, and three doses are given according to the immunization program of 0, 2 and 6 months. Nine-valent refers to the ability to prevent nine high-risk viruses, mainly preventing a variety of diseases caused by HPV subtypes 6, 11, 16, 18, 31, 33, 45, 52 and 58 viruses. These include the seven high-risk types 16, 18, 31, 33, 45, 52, and 58, which can prevent cervical cancer and other cancers of the reproductive system. Severe allergic reactions to any of the active ingredients or excipients in the HPV vaccine are contraindications. Individuals who develop an allergy after vaccination should not be revaccinated. If a woman is pregnant or planning to become pregnant, it is recommended to delay or interrupt the vaccination and then administer the vaccine after the pregnancy is over. In addition, not all people are suitable for the nine-valent vaccine, and it is recommended that women who need to be vaccinated should do so under the supervision of a doctor.